Bupropion Sustained Release Treatment Reduces Fatigue in Cancer Patients

Canadian Journal of Psychiatry

Volumn 49, Issue 2, 2004, Pages 139-144

  Cullum, Jodi L ^a   Wojciechowski, Agnieszka E ^b   Pelletier, Guy ^a,b   Simpson, J Steven A ^c,d  

^a TOM BAKER CANCER CENTRE   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c FOOTHILLS HOSPITAL   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

Author keywords

Bupropion; Cancer; Clinical case series; Fatigue; Treatment

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE DERIVATIVE; ANTIDEPRESSANT AGENT; CORTICOSTEROID; FLUOXETINE; METHYLPHENIDATE; MIRTAZAPINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ADULT; AGED; AGITATION; ANXIETY; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DEPRESSION; DRUG EFFICACY; EYE IRRITATION; FATIGUE; FEMALE; FOCAL EPILEPSY; HEADACHE; HUMAN; HYPERREFLEXIA; INSOMNIA; IRRITABILITY; LACRIMATION; MALE; MENTAL DISEASE; NAUSEA; OUTPATIENT; PRURITUS; QUALITY OF LIFE; SEIZURE; SIDE EFFECT; SUSTAINED DRUG RELEASE; TREMOR; VISUAL IMPAIRMENT; XEROSTOMIA;

EID: 1642368065     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: 10.1177/070674370404900209     Document Type: Article

References (44)

1. Valentine AD, Meyers CA. Cognitive and mood disturbance as causes and symptoms of fatigue in cancer subjects. Cancer 2001;92(Suppl 6):1694-8.
2. Schwartz AL, Nail LM, Chen S, Meek P, Barsevick AM, King ME, and others. Fatigue patterns observed in subjects receiving chemotherapy and radiotherapy. Cancer Invest 2000;18(1):11-9.
3. NIH state-of-the-science conference statement on symptom management in cancer: pain, depression and fatigue; 2002. http://consensus.nih.gov. Accessed November 14, 2002.
4. Mock V, Atkinson A, Barsevick A, Cella D, Cimprich B, Cleeland C, and others. NCCN practice guidelines for cancer-related fatigue. Oncology (Huntingt) 2000;14(11 A):151-61.
5. Cleeland CS. Cancer-related symptoms. Semin Radiat Oncol 2000;10:175-90.
6. Servaes P, Verhagen C, Bleijenberg G. Fatigue in cancer patients during and after treatment: prevalence, correlates and interventions. Eur J Cancer 2002;38(1):27-43.
7. Cella D, Davis K, Breitbart W, Curt G. Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol 2001;19:3385-91.
8. Winningham ML. Strategies for managing cancer-related fatigue syndrome: a rehabilitation approach. Cancer 2001;92(Suppl 4):988-97.
9. Masand P, Chaudhary P. Methylphenidate treatment of poststroke depression in a patient with global aphasia. Ann Clin Psychiatry 1994;6:271-4.
10. Masand P, Pickett P, Murray GB. Psychostimulants for secondary depression in medical illness. Psychosomatics 1991;32:203-8.
11. Olin J, Masand P. Psychostimulants for depression in hospitalized cancer subjects. Psychosomatics 1996;37:57-62.
12. Weitzner MA, Meyers CA, Valentine AD. Methylphenidate in the treatment of neurobehavioural slowing associated with cancer and cancer treatment. J Neuropsychiatry Clin Neurosci 1995;7:347-50.
13. Meyers CA, Weitzner MA, Valentine AD, Levin VA. Methylphenidate therapy improves cognition, mood and function of brain tumor subjects. J Clin Oncol 1998;16:2522-7.
14. Cleare AJ, Heap E, Malhi GS, Wessely S, O'Keane V, Miell J. Low-dose hydrocortisone in chronic fatigue syndrome: a randomised crossover trial. Lancet 1999;353:455-8
15. Holland JC, Romano SR, Heiligenstein JH, Tepner RG, Wilson MG. A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. Psychooncology 1998;7:291-300.
16. Passik SD, Kirsh KL, Theobald D, Donaghy K, Holtsclaw E, Edgerton S, and others. Use of a depression screening tool and a fluoxetine-based algorithm to improve the recognition and treatment of depression in cancer patients: a demonstration project. J Pain Symptom Manage 2002;24:318-27.
17. Fisch MJ, Loehrer PJ, Kristeller J, Passik S, Jung SH, Shen J, and others. Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier oncology group. J Clin Oncol 2003;21:1937-43.
18. Pezzella G, Moslinger-Gehmayr R, Contu A. Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline. Breast Cancer Res Treat 2001;70(1):1-10.
19. Weitzner MA, Moncello J, Jacobsen PB, Minton S. A pilot trial of paroxetine for the treatment of hot flashes and associated symptoms in women with breast cancer. J Pain Symptom Manage 2002;23:337-45.
20. Theobald D, Kirsch KL, Holtsclaw E, Donaghy K, Passik SD. An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. J Pain Symptom Manage 2002;23:442-7.
21. Van Gool AR, Bannink M, Stronks DL, Vos MS. Mirtazapine in cancer patients. J Pain Symptom Manage 2003;25(1):7-8.
22. Stahl SM. The psychopharmacology of energy and fatigue. J Clin Psychiatry 2002;63(1):7-8.
23. Schwartz L, Lander M, Chochinov HM. Current management of depression in cancer patients. Oncology (Huntingt) 2002;16:1102-15.
24. Burks TF. New agents for the treatment of cancer-related fatigue. Cancer 2001;92(Suppl 6):1714-8.
25. Vassout A, Bruinink A, Krauss J, Waldmeier P, Bischoff S. Regulation of dopamine receptors by bupropion: comparison with antidepressants and CNS stimulants. J Recept Res 1993;13:341-54.
26. Hoffman DC. The use of place conditioning in studying the neuropharmacology of drug reinforcement, Brain Res Bull 1989;23:373-87.
27. Tucker WE. Preclinical toxicology of bupropion: an overview. J Clin Psychiatry 1983;44(5):60-2.
28. Settle EC, Stahl SM, Batey SR, Johnston JA, Ascher JA. Safety profile of sustained-release bupropion in depression: results of three clinical trials. Clin Ther 1999;21:454-63.
29. Kirksey DF, Harto-Truax N. Private practice evaluation of the safety and efficacy of bupropion in depressed outpatients. J Clin Psychiatry 1983;44:143-7.
30. Wender PH, Reimherr FW. Bupropion treatment of attention-deficit hyperactivity disorder in adults. Am J Psychiatry 1990;147:1018-20.
31. Wilens TE, Biederman J, Spencer TJ, Prince J. Pharmacotherapy of adult attention deficit/hyperactivity disorder: a review. J Clin Psychopharmacol 1995;15:270-9.
32. Cantwell DP. ADHD through the life span: the role of bupropion in treatment. J Clin Psychiatry 1998;59(4):92-4.
33. Barrickman LL, Perry PJ, Allen AJ, and others. Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1995;34:649-57.
34. Cyr M, Brown CS. Current drug therapy recommendations for the treatment of attention deficit hyperactivity disorder. Drugs 1998;56:215-23.
35. Findling RL, Dogin JW. Psychopharmacology of ADHD: children and adolescents. J Clin Psychiatry 1998;59(Suppl 7):42-9.
36. Wender PH. Pharmacotherapy of attention-deficit/hyperactivity disorder in adults. J Clin Psychiatry 1998;59(7):76-9.
37. Popper CW. Pharmacologic alternatives to psychostimulants for the treatment of attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 2000;9:605-46.
38. Mauskopf JA, Simeon GP, Miles MA, Westlund RE, Davison JRT. Functional status in depressed subjects: the relationship to disease severity and disease resolution. J Clin Psychiatry 1996;57:588-92.
39. Goodnick PJ. Bupropion in chronic fatigue syndrome. Am J Psychiatry 1990;147:1091.
40. Goodnick PJ, Sandoval R, Brickman A, Klimas NG. Bupropion treatment of luoxetine-resistant chronic fatigue syndrome. Biol Psychiatry 1992;32:834-8.
41. Green TR. Bupropion for SSRI-induced Fatigue. J Clin Psychiatry 1997;58:174.
42. Duffy JD, Campbell J. Bupropion for the treatment of fatigue associated with multiple sclerosis. Psychosomatics 1994;35:170-1.
43. Clinical Global Impression (CGI). In: Guy W, editor. ECDEU assessment for psychopharmacology. Rev ed. Rockville (MD): National Institute of Mental Health; 1976. p 217-22.
44. Kumar R. Important safety information regarding bupropion. Mississauga: GlaxoSmithKline; July 3; 2001. Www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/advisory/industry/zyban_e.pdf. Accessed September 24, 2002.